# Stem Cell Transplant for Hemoglobinopathy

> **NCT00176852** · PHASE2,PHASE3 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 22 (actual)

## Conditions studied

- Sickle Cell Disease
- Thalassemia
- Severe Congenital Neutropenia
- Diamond-Blackfan Anemia
- Shwachman-Diamond Syndrome

## Interventions

- **DRUG:** Busulfan, Fludarabine, ATG, TLI
- **DRUG:** Busulfan, Cyclophosphamide, ATG, GCSF
- **DRUG:** Campath, Fludarabine, Cyclophosphamide
- **RADIATION:** Total Body Irradiation
- **PROCEDURE:** Stem cell infusion

## Key facts

- **NCT ID:** NCT00176852
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2014-03
- **Final completion:** 2020-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176852, "Stem Cell Transplant for Hemoglobinopathy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00176852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*